ClinicalTrials.gg
RecruitingNCT07412041PERCCUpdated Aug 5, 2026

Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study

An interventional study of PERCC in Stage II Lung Cancer, Lung Cancer and Non-small Cell Lung Cancer, sponsored by Dana-Farber Cancer Institute. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-05.

Primary conditionCarcinoma, Non-Small-Cell LungRegistry: Lung NeoplasmsReclassifiedWhy we changed it
Registry
Lung Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Non-Small-Cell Lung
Why
  1. The study's listed conditions name Carcinoma, Non-Small-Cell Lung, a narrower term within Lung Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Dana-Farber Cancer Institute · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Carcinoma, Non-Small-Cell Lung by Dana-Farber Cancer Institute — 4 open to participants now, 7 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Dana-Farber Cancer Institute.

Planned enrollment
13th of 19
20 · median 30
Started
2026
the only one that year
No phase
3 of 20
1 open now
Registered
19th of 20
by date

Among the 20 studies in Carcinoma, Non-Small-Cell Lung by Dana-Farber Cancer Institute, this one is the 13th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2026, is one of 3 with no phase, and was the 19th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

4 of the 20 studies in Carcinoma, Non-Small-Cell Lung by Dana-Farber Cancer Institute are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Carcinoma, Non-Small-Cell Lung by Dana-Farber Cancer Institute, or all of them as a file.
02

Study summary

The purpose of this study is to test the feasibility of the Precise Exercise Regimen for Cancer Care (PERCC) exercise program in participants with stage II-III primary lung cancer.

Read the detailed description

This research study is a feasibility pilot study and to test the feasibility of the Precise Exercise Regimen for Cancer Care (PERCC) exercise program in participants with stage II-III primary lung cancer.

The research study procedures include screening for eligibility including evaluations of fitness and physical health, surveys, and study entry visits.

Participation in the study is expected to be about 24 weeks.

It is expected that about 20 people will take part in this research study

03

Conditions studied

  • Stage II Lung Cancer
  • Lung Cancer
  • Non-small Cell Lung Cancer
  • NSCLC

Browse trials for

Keywords

  • Stage II Lung Cancer
  • Lung Cancer
  • Non-small Cell Lung Cancer
  • NSCLC
04

In context

Carcinoma, Non-Small-Cell Lung Reclassified

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

This study's planned enrollment of 20 is below the median of 62 across 6,034 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.

Browse Carcinoma, Non-Small-Cell Lung studies →

Lead sponsor

Dana-Farber Cancer Institute is the lead sponsor of 836 studies on the registry; 121 are open to participants now.

Of its 114 completed or terminated interventional studies of FDA-regulated products, 78 (68%) have results posted.

Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years at time of diagnosis; due to the rarity of the disease in those \<18 years, this age bracket will not be included.
  • diagnosed with stage II or III non-small cell lung cancer (NSCLC) and has not started lung cancer treatment.
  • Patient's treatment plan is to receive therapy (defined as chemotherapy, chemotherapy and immunotherapy, or chemotherapy and radiation therapy) followed by surgical treatment. Patients will be enrolled at least three weeks prior to receiving their first neoadjuvant treatment.
  • Ability to follow directions and complete questionnaires in English and/or Spanish.
  • Ability to understand and the willingness to sign a written document prior to any study-related procedures.
  • Willing to travel to DFCI for necessary data collection.

Exclusion criteria

Exclusion Criteria:

  • Patients who are morbidly obese (>40 kg/m2) or Anorexic (BMI\<17 kg/m2).
  • Unstable comorbidities that contraindicate participation in exercise program compliance. Patients with unstable comorbidities may develop unexpected adverse events from exercise. For the purpose of patients' safety, as well as because part of this study involves remote, home-based exercise where close supervision is not possible, patients with unstable medical conditions are excluded. Study staff will identify untreated or unmanaged conditions when screening and treating MDs must provide clearance prior to patient enrollment.
  • Patients with alcohol or drug abuse, significant mental or emotional problems that would interfere with compliance (assessed by NCCN Distress Thermometer).
  • Patients scheduled to receive single modality cancer treatment (unimodal therapy), scheduled surgery within 2 weeks of the pre-treatment clinic visit, or for whom treatment has already started.
  • Patients who are pregnant, or plan to become pregnant during study duration will be excluded due to the unknown nature of exercise on developing fetuses.
  • Subjects who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    PERCC

    Receives personalized virtual exercise program (aerobic and resistance exercise) 1x weekly for patients with lung cancer who plan on receiving neoadjuvant treatment followed by surgery.

    Behavioral: PERCC

Interventions

  • BehavioralPERCC

    Personalized at-home exercise program, including aerobic and resistance exercise. Supervised by trained exercise professional via ZOOM (HIPPA complaint video conferencing platform). Study equipment of Fitbit and resistance bands will be provided to participants.

    Also known as: Precise Exercise Regimen for Cancer Care (PERCC)

07

What researchers measure

Primary outcomes

  1. Attendance of Exercise Sessions (Feasibility)

    Defined as the proportion of enrolled participants who complete ≥80% of the prescribed exercise sessions.

    Time frame: From first exercise session to final exercise session (up to 24 weeks)

Other outcomes

  1. Treatment Delays

    Time frame: Defined as time between neoadjuvant therapy and surgery

  2. Physical Function (Short Physical Performance Battery - SPPB)

    The SPPB is comprised of three sections: 1) balance with feet together, semi tandem, and full tandem is held for up to 10 seconds with no support (seconds); 2) usual gait speed over four meters is timed (seconds); and 3) chair stand where the time(s) to complete five chair sit-to-stands is recorded.

    Time frame: From baseline (T0) to intermodal visit (T1) to end-of-study (T2) - approximately 24 weeks

  3. Quality of Life (Functional Assessment of Cancer Therapy - Lung [FACT-L])

    Assessed by the Functional Assessment of Cancer Therapy - Lung (FACT-L), a 36-item instrument, which specifically determines the QoL in patients with lung cancer with subscales assessing "physical well-being", "emotional well-being", "social well-being", "functional well-being", and "disease-specific items."

    Time frame: From baseline (T0) to intermodal visit (T1) to end-of-study (T2) - approximately 24 weeks

  4. Fatigue (Functional Assessment of Cancer Therapy - Fatigue [FACT-F])

    Assessed by the Functional Assessment of Cancer Therapy - Fatigue (FACT-F), which a 13-item instrument, added to the end of the FACT-L, which assessed self-reported fatigue and impact on daily activities.

    Time frame: From baseline (T0) to intermodal visit (T1) to end-of-study (T2) - approximately 24 weeks

  5. Nutritional Risk (Nutriscore)

    Nutritional risk will be assessed by a brief survey called the Nutriscore

    Time frame: From baseline (T0) to intermodal visit (T1) to end-of-study (T2) - approximately 24 weeks

  6. Personal Habits (Personal Habits Questionnaire)

    The Personal Habits Questionnaire will be used to ascertain an idea of participants' habits in their personal lives.

    Time frame: From baseline (T0) to intermodal visit (T1) to end-of-study (T2) - approximately 24 weeks

  7. Smoking and Tobacco Usage

    Time frame: From baseline (T0) to intermodal visit (T1) to end-of-study (T2) - approximately 24 weeks

  8. Emotional Status (Thoughts and Feelings Questionnaire)

    The Thoughts and Feelings Questionnaire will be administered to ascertain participants' emotional status.

    Time frame: From baseline (T0) to intermodal visit (T1) to end-of-study (T2) - approximately 24 weeks

  9. Exercise Self-Efficacy (Exercise Confidence Survey)

    Time frame: From baseline (T0) to intermodal visit (T1) to end-of-study (T2) - approximately 24 weeks

  10. Social Support (Social Activities Survey)

    Time frame: From baseline (T0) to intermodal visit (T1) to end-of-study (T2) - approximately 24 weeks

  11. Subjective Social Status (Society and Community Questionnaire)

    The Society and Community Questionnaire will determine where participants feel they fall in society using subjective social status ladders.

    Time frame: From baseline (T0) to intermodal visit (T1) to end-of-study (T2) - approximately 24 weeks

  12. Healthcare Cost and Utilization

    The Healthcare Cost and Utilization Questionnaire that will be used measures PERCC intervention's impact on healthcare cost and utilization. This established survey looks at length of stay, hospital admissions, emergency room visits and healthcare-associated costs.

    Time frame: From baseline (T0) to intermodal visit (T1) to end-of-study (T2) - approximately 24 weeks

  13. Biomarker Levels

    Biomarkers will be analyzed via blood

    Time frame: From baseline (T0) to intermodal visit (T1) to end-of-study (T2) - approximately 24 weeks

  14. Body Composition

    Bioelectrical Impedance Analysis (BIA), and blood pressure as measured twice on both arms with a seated position with a minimum of 1-minute interval and the higher pressure will be recorded when there are differences. BIA: Assessed via bioelectrical impedance using a validated device (Tanita 780, Arlington Heights, IL). Participants will be asked to remove their shoes and socks after which height will be taken using a stadiometer they will then proceed to move to the BIA and stand still on the device while holding the handles with their hands at their sides. The device will estimate body fat using an algorithm based on their age, sex, height, and body weight.

    Time frame: From baseline (T0) to intermodal visit (T1) to end-of-study (T2) - approximately 24 weeks

  15. Hip and Waist Circumference

    Hip and waist circumference will be assessed and recorded in cm.

    Time frame: From baseline (T0) to intermodal visit (T1) to end-of-study (T2) - approximately 24 weeks

  16. Functional Mobility (Activity Measure for Post Acute Care [AM-PAC])

    The Activity Measure for Post Acute Care (AM-PAC) enables functional mobility assessment and assignment of functional stage. Participants will complete the AM-PAC questionnaire at T0 and every two weeks throughout their participation in the study.

    Time frame: Baseline (T0) to intermodal visit (T1) to end-of-study visit (T2) - approximately 24 weeks

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: DFCI - Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Mar 2027, 14 months after the start.

Of 345 non-industry interventional studies with no phase under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 97. This study's planned 14 months is below that.

Counting every sponsor, half of 361 studies reached it within 51 months; a quarter within 26 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2026
First posted
Feb 17, 2026
StartActual
Jan 22, 2026
Primary completionEst.
Mar 30, 2027
CompletionEst.
Mar 30, 2028
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07412041
Responsible party
Christina Dieli-Conwright, PhD (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Feb 17, 2026
Start date
Jan 22, 2026
Primary completion
Mar 30, 2027 (estimated)
Completion
Mar 30, 2028 (estimated)
Last update
Aug 5, 2026

Study contacts

Christina Dieli-Conwright, PhD, MPH
Contact
christinam_dieli-conwright@dfci.harvard.edu
617-582-8321
Christina Dieli-Conwright, PhD, MPH
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion